Jyothi Prya Jagannathan, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diagnostic Imaging | 4 | 2016 | 3507 | 0.390 |
Why?
|
| Sarcoma | 2 | 2016 | 1897 | 0.300 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2016 | 1363 | 0.290 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 2957 | 0.130 |
Why?
|
| Leiomyosarcoma | 1 | 2016 | 477 | 0.100 |
Why?
|
| Empyema, Pleural | 1 | 2011 | 62 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5442 | 0.090 |
Why?
|
| Enteritis | 1 | 2011 | 165 | 0.090 |
Why?
|
| Teratoma | 1 | 2011 | 395 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 547 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 299 | 0.070 |
Why?
|
| Phlebography | 1 | 2008 | 333 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2011 | 1378 | 0.070 |
Why?
|
| Pleural Neoplasms | 1 | 2011 | 607 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2011 | 1533 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2008 | 776 | 0.060 |
Why?
|
| Sirolimus | 1 | 2011 | 1564 | 0.060 |
Why?
|
| Pelvis | 1 | 2008 | 730 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 847 | 0.050 |
Why?
|
| Angiography | 1 | 2008 | 1639 | 0.050 |
Why?
|
| Pulmonary Veins | 1 | 2008 | 761 | 0.050 |
Why?
|
| Lymphoma | 1 | 2011 | 1877 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 2109 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2011 | 20129 | 0.050 |
Why?
|
| Melanoma | 2 | 2011 | 5510 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 1596 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2011 | 3474 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2008 | 1206 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2010 | 2265 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2488 | 0.040 |
Why?
|
| Radiology | 1 | 2010 | 2100 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 12959 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 2942 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2011 | 4445 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 4034 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 1671 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 5686 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 4838 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 9274 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7279 | 0.030 |
Why?
|
| Positron-Emission Tomography | 3 | 2011 | 6234 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 9239 | 0.020 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2009 | 35 | 0.020 |
Why?
|
| Humans | 12 | 2016 | 744343 | 0.020 |
Why?
|
| Vincristine | 1 | 2011 | 1039 | 0.020 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2009 | 166 | 0.020 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 87 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 693 | 0.020 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2009 | 169 | 0.020 |
Why?
|
| Nose Neoplasms | 1 | 2009 | 246 | 0.020 |
Why?
|
| Prednisone | 1 | 2011 | 1574 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 2242 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 13695 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 1261 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2008 | 987 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 2234 | 0.020 |
Why?
|
| Benzamides | 1 | 2008 | 1379 | 0.010 |
Why?
|
| Neoplasms | 1 | 2010 | 21683 | 0.010 |
Why?
|
| Aged | 5 | 2011 | 163280 | 0.010 |
Why?
|
| Radiography | 1 | 2011 | 7023 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2266 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 11366 | 0.010 |
Why?
|
| Female | 6 | 2011 | 380194 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 11031 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 3143 | 0.010 |
Why?
|
| Middle Aged | 4 | 2011 | 213383 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 4262 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14722 | 0.010 |
Why?
|
| Male | 4 | 2011 | 350118 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 11524 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 19905 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 57776 | 0.000 |
Why?
|
| Adult | 2 | 2009 | 214055 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2011 | 63114 | 0.000 |
Why?
|
| Mutation | 1 | 2008 | 29786 | 0.000 |
Why?
|
| United States | 1 | 2010 | 69872 | 0.000 |
Why?
|
| Adolescent | 1 | 2008 | 85781 | 0.000 |
Why?
|